Skip to main content
SHANGHAI RENDU BIOTECHNOLOGY CO., LTD. logo

SHANGHAI RENDU BIOTECHNOLOGY CO., LTD. — Investor Relations & Filings

Ticker · 688193 ISIN · CNE1000059K5 LEI · 300300YIUCE4LPCEH293 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 400 across all filing types
Latest filing 2026-06-03 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688193

About SHANGHAI RENDU BIOTECHNOLOGY CO., LTD.

https://www.rdbio.com/en/

Shanghai Rendu Biotechnology Co., Ltd. specializes in the development, manufacturing, and commercialization of molecular diagnostic products. The company leverages its proprietary RNA-based isothermal amplification technology, known as Simultaneous Amplification and Testing (SAT), to provide rapid and sensitive detection solutions. Its product portfolio primarily focuses on clinical diagnostics for infectious diseases, including sexually transmitted infections, respiratory tract infections, and blood-borne pathogens. Rendu Biotechnology offers integrated platforms that combine automated nucleic acid extraction with high-throughput amplification, aiming to improve laboratory efficiency and diagnostic accuracy. By targeting active infection markers through RNA detection, the company provides clinicians with precise tools for disease management and public health monitoring.

Recent filings

Filing Released Lang Actions
中国国际金融股份有限公司关于上海仁度生物科技股份有限公司差异化分红事项的核查意见
Regulatory Filings Classification · 72% confidence The document is a formal sponsor verification opinion (“核查意见”) issued by the company’s underwriting/sponsor institution (中金公司) regarding the differentiated dividend distribution plan of Shanghai Rendu Biotechnology. It does not itself present full financial statements (10-K, IR), nor is it a shareholder voting result announcement (DVA) or proxy solicitation. It is a compliance/legal attestation required under listing rules, fitting the definition of a general regulatory announcement/fallback for miscellaneous filings. Therefore, it is classified as a Regulatory Filing (RNS).
2026-06-03 Chinese
2025年年度权益分派实施公告
Notice of Dividend Amount Classification · 91% confidence The document is an official announcement by Shanghai Rendu Biotechnology Co., Ltd. detailing the 2025 annual profit distribution (dividend) implementation: per-share cash dividend, record date, ex-dividend date, payment date, tax treatment, and related procedures. It clearly fits the category of a Notice of Dividend Amount rather than a financial report, management change, or regulatory filing. Thus it should be classified as DIV.
2026-06-03 Chinese
2025年年度股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 92% confidence The document is an announcement of the resolutions passed at the 2025 Annual General Meeting of Shanghai Rendu Biotechnology Co., Ltd., detailing attendance, proposals considered, and voting results on each agenda item. This matches the definition of “Declaration of Voting Results & Voting Rights Announcements” (Code: DVA).
2026-05-21 Chinese
北京市嘉源律师事务所关于上海仁度生物科技股份有限公司2025年年度股东会的法律意见书
Regulatory Filings Classification · 85% confidence The document is a legal opinion letter issued by a law firm regarding the convening, attendance, voting procedures, and results of the 2025 Annual General Meeting of Shanghai RenDu Biotech. It is essentially an attestation/certification by external counsel rather than the substantive filing of the AGM materials or voting results by the company itself. According to the certification rule, such attestations should be classified under Regulatory Filings (RNS) as they do not constitute the report itself but rather a legal opinion or confirmation.
2026-05-21 Chinese
中国国际金融股份有限公司关于上海仁度生物科技股份有限公司2025年度持续督导跟踪报告
Regulatory Filings Classification · 72% confidence The document is titled as the “2025年度持续督导跟踪报告” issued by the sponsor (保荐机构) of Shanghai Rendu Biotechnology Co., Ltd. and contains the sponsor’s continuous supervision work, corporate governance checks, risk analysis, and detailed financial metrics for the full 2025 year. It is not an annual report (10-K), audit report, interim/quarterly report, earnings release, or investor presentation, nor does it announce a vote result, dividend, M&A, or share issue. Rather, it is a mandated regulatory compliance report by the sponsor under Shanghai Stock Exchange rules. It therefore falls into the fallback Regulatory Filings category (RNS).
2026-05-21 Chinese
关于控股股东筹划控制权变更事项进展暨股票复牌公告
Regulatory Filings Classification · 78% confidence The document is a stock exchange announcement disclosing the suspension and resumption of trading due to a planned change of controlling shareholder. It is not the full M&A transaction document itself, nor a detailed take-over bid circular, but a regulatory disclosure under exchange rules. Therefore it falls under the general "Regulatory Filings" category.
2026-05-14 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.